Edward Nash
Stock Analyst at Canaccord Genuity
(3.94)
# 547
Out of 5,240 analysts
83
Total ratings
51.32%
Success rate
11.5%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $587 → $578 | $518.87 | +11.40% | 13 | May 7, 2026 | |
| KYMR Kymera Therapeutics | Initiates: Buy | $106 | $85.59 | +23.85% | 1 | May 6, 2026 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 → $49 | $7.60 | +544.74% | 3 | May 4, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $62 → $64 | $59.12 | +8.25% | 2 | Apr 29, 2026 | |
| GPCR Structure Therapeutics | Initiates: Buy | $101 | $38.08 | +165.23% | 1 | Apr 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Buy | $47 → $56 | $44.55 | +25.70% | 11 | Apr 14, 2026 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $8 | $1.36 | +488.24% | 4 | Apr 6, 2026 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 → $5 | $1.05 | +376.19% | 3 | Apr 1, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $100 → $110 | $57.08 | +92.71% | 13 | Mar 26, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $89 → $130 | $83.94 | +54.87% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4 → $3 | $1.17 | +156.41% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.26 | +1,006.19% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $107 | $31.70 | +237.54% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.54 | +261.01% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 | $32.51 | +90.71% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.33 | +410.51% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $4.56 | -56.14% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.60 | +30,136.86% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.24 | +407.81% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $26.46 | +209.90% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $29.17 | +64.55% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.71 | +11,283.54% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 7, 2026
Maintains: Buy
Price Target: $587 → $578
Current: $518.87
Upside: +11.40%
Kymera Therapeutics
May 6, 2026
Initiates: Buy
Price Target: $106
Current: $85.59
Upside: +23.85%
Sagimet Biosciences
May 4, 2026
Maintains: Buy
Price Target: $28 → $49
Current: $7.60
Upside: +544.74%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintains: Buy
Price Target: $62 → $64
Current: $59.12
Upside: +8.25%
Structure Therapeutics
Apr 27, 2026
Initiates: Buy
Price Target: $101
Current: $38.08
Upside: +165.23%
Travere Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $47 → $56
Current: $44.55
Upside: +25.70%
Cardiol Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $8
Current: $1.36
Upside: +488.24%
Rani Therapeutics Holdings
Apr 1, 2026
Maintains: Buy
Price Target: $9 → $5
Current: $1.05
Upside: +376.19%
Corcept Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $100 → $110
Current: $57.08
Upside: +92.71%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $89 → $130
Current: $83.94
Upside: +54.87%
Mar 13, 2026
Maintains: Hold
Price Target: $4 → $3
Current: $1.17
Upside: +156.41%
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.26
Upside: +1,006.19%
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $31.70
Upside: +237.54%
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $5.54
Upside: +261.01%
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $32.51
Upside: +90.71%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.33
Upside: +410.51%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $4.56
Upside: -56.14%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.60
Upside: +30,136.86%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.24
Upside: +407.81%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $26.46
Upside: +209.90%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $29.17
Upside: +64.55%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.71
Upside: +11,283.54%